Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBT Margin (2016 - 2025)

Historic EBT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 1.97%.

  • Akebia Therapeutics' EBT Margin rose 555100.0% to 1.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.79%, marking a year-over-year decrease of 3187300.0%. This contributed to the annual value of 43.33% for FY2024, which is 4759200.0% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' EBT Margin is 1.97%, which was up 555100.0% from 0.4% recorded in Q2 2025.
  • Akebia Therapeutics' EBT Margin's 5-year high stood at 22.98% during Q2 2022, with a 5-year trough of 159.32% in Q2 2021.
  • Moreover, its 5-year median value for EBT Margin was 49.04% (2024), whereas its average is 56.86%.
  • Data for Akebia Therapeutics' EBT Margin shows a peak YoY increase of 2767200bps (in 2021) and a maximum YoY decrease of -646800bps (in 2021) over the last 5 years.
  • Akebia Therapeutics' EBT Margin (Quarter) stood at 122.1% in 2021, then soared by 90bps to 11.66% in 2022, then skyrocketed by 96bps to 0.48% in 2023, then crashed by -10158bps to 49.04% in 2024, then skyrocketed by 104bps to 1.97% in 2025.
  • Its EBT Margin stands at 1.97% for Q3 2025, versus 0.4% for Q2 2025 and 10.66% for Q1 2025.